Cargando…

Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic

This consensus statement about the indications and modalities of corticosteroid treatment in the context of the COVID-19 pandemic was jointly written by experts from the French Association of Otology and Oto-Neurology (AFON) and from the French Society of Otorhinolaryngology, Head and Neck Surgery (...

Descripción completa

Detalles Bibliográficos
Autores principales: Herman, P., Vincent, C., Parietti Winkler, C., Loundon, N., Couloigner, V., Tankere, F., Tringali, S., Gallet, P., Papon, J.-F., Montava, M., Lavieille, J.-P., Charpiot, A., Schmerber, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198134/
https://www.ncbi.nlm.nih.gov/pubmed/32482571
http://dx.doi.org/10.1016/j.anorl.2020.04.014
_version_ 1783528937982263296
author Herman, P.
Vincent, C.
Parietti Winkler, C.
Loundon, N.
Couloigner, V.
Tankere, F.
Tringali, S.
Gallet, P.
Papon, J.-F.
Montava, M.
Lavieille, J.-P.
Charpiot, A.
Schmerber, S.
author_facet Herman, P.
Vincent, C.
Parietti Winkler, C.
Loundon, N.
Couloigner, V.
Tankere, F.
Tringali, S.
Gallet, P.
Papon, J.-F.
Montava, M.
Lavieille, J.-P.
Charpiot, A.
Schmerber, S.
author_sort Herman, P.
collection PubMed
description This consensus statement about the indications and modalities of corticosteroid treatment in the context of the COVID-19 pandemic was jointly written by experts from the French Association of Otology and Oto-Neurology (AFON) and from the French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL). There is currently not enough data in favour of danger or benefit from corticosteroids in COVID-19, so until this matter is resolved it is advisable to limit their indications to the most serious clinical pictures for which it is well established that this type of treatment has a positive impact on the progression of symptoms. In Grade V and VI Bell's palsy according to the House-Brackmann grading system, a week's course of oral corticosteroids is recommended. Corticosteroid therapy is also recommended in cases of sudden hearing loss of more than 60 dB, either in the form of intratympanic injections or a week's course of oral medication. In rhinology, there is no indication for systemic corticosteroid therapy in the current situation. However, patients are advised to continue with their local corticosteroid therapy in the form of a nasal spray or by inhalation. Treatments with corticosteroid nasal sprays can still be prescribed if there is no alternative. Finally, systemic or local corticosteroid therapy is not indicated for bacterial ENT infections.
format Online
Article
Text
id pubmed-7198134
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-71981342020-05-05 Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic Herman, P. Vincent, C. Parietti Winkler, C. Loundon, N. Couloigner, V. Tankere, F. Tringali, S. Gallet, P. Papon, J.-F. Montava, M. Lavieille, J.-P. Charpiot, A. Schmerber, S. Eur Ann Otorhinolaryngol Head Neck Dis Article This consensus statement about the indications and modalities of corticosteroid treatment in the context of the COVID-19 pandemic was jointly written by experts from the French Association of Otology and Oto-Neurology (AFON) and from the French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL). There is currently not enough data in favour of danger or benefit from corticosteroids in COVID-19, so until this matter is resolved it is advisable to limit their indications to the most serious clinical pictures for which it is well established that this type of treatment has a positive impact on the progression of symptoms. In Grade V and VI Bell's palsy according to the House-Brackmann grading system, a week's course of oral corticosteroids is recommended. Corticosteroid therapy is also recommended in cases of sudden hearing loss of more than 60 dB, either in the form of intratympanic injections or a week's course of oral medication. In rhinology, there is no indication for systemic corticosteroid therapy in the current situation. However, patients are advised to continue with their local corticosteroid therapy in the form of a nasal spray or by inhalation. Treatments with corticosteroid nasal sprays can still be prescribed if there is no alternative. Finally, systemic or local corticosteroid therapy is not indicated for bacterial ENT infections. Elsevier Masson SAS. 2020-09 2020-05-04 /pmc/articles/PMC7198134/ /pubmed/32482571 http://dx.doi.org/10.1016/j.anorl.2020.04.014 Text en © 2020 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Herman, P.
Vincent, C.
Parietti Winkler, C.
Loundon, N.
Couloigner, V.
Tankere, F.
Tringali, S.
Gallet, P.
Papon, J.-F.
Montava, M.
Lavieille, J.-P.
Charpiot, A.
Schmerber, S.
Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic
title Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic
title_full Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic
title_fullStr Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic
title_full_unstemmed Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic
title_short Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic
title_sort consensus statement. corticosteroid therapy in ent in the context of the covid-19 pandemic
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198134/
https://www.ncbi.nlm.nih.gov/pubmed/32482571
http://dx.doi.org/10.1016/j.anorl.2020.04.014
work_keys_str_mv AT hermanp consensusstatementcorticosteroidtherapyinentinthecontextofthecovid19pandemic
AT vincentc consensusstatementcorticosteroidtherapyinentinthecontextofthecovid19pandemic
AT pariettiwinklerc consensusstatementcorticosteroidtherapyinentinthecontextofthecovid19pandemic
AT loundonn consensusstatementcorticosteroidtherapyinentinthecontextofthecovid19pandemic
AT couloignerv consensusstatementcorticosteroidtherapyinentinthecontextofthecovid19pandemic
AT tankeref consensusstatementcorticosteroidtherapyinentinthecontextofthecovid19pandemic
AT tringalis consensusstatementcorticosteroidtherapyinentinthecontextofthecovid19pandemic
AT galletp consensusstatementcorticosteroidtherapyinentinthecontextofthecovid19pandemic
AT paponjf consensusstatementcorticosteroidtherapyinentinthecontextofthecovid19pandemic
AT montavam consensusstatementcorticosteroidtherapyinentinthecontextofthecovid19pandemic
AT lavieillejp consensusstatementcorticosteroidtherapyinentinthecontextofthecovid19pandemic
AT charpiota consensusstatementcorticosteroidtherapyinentinthecontextofthecovid19pandemic
AT schmerbers consensusstatementcorticosteroidtherapyinentinthecontextofthecovid19pandemic